Experience

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on offering of 5,227,272 shares of common stock of Allakos Inc. for…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125…

Davis Polk advised Oryzon Genomics, S.A. on its €20 million private placement of its ordinary shares pursuant to a capital increase. The offering consisted of a private placement to…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering of common stock by Seattle Genetics, Inc. for gross…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $150 million SEC-registered common stock and pre-funded warrants…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an $86.25 million public offering of common stock of Forty Seven, …

Davis Polk advised the underwriter in connection with a secondary offering of 12,000,000 American Depositary Shares of Hutchison China Meditech Limited (“Chi-Med”), each representing five…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €5 billion aggregate principal amount of notes by Medtronic Global…

Davis Polk advised McKesson Corporation on Change Healthcare Inc.’s SEC-registered initial public offering of 49,285,713 shares of its common stock at a price to the public of $13 per…

Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq…